Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study.

ABSTRACT:

Objective

To assess present angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) use among patients with proteinuric chronic kidney disease (CKD) and examine barriers limiting this guideline-concordant care.

Patients and methods

Using a nationwide database containing patient-level claims and integrated clinical information, we examined current ACEI/ARB prescriptions on the index date (April 15, 2017) and prior ACEI/ARB use in 41,743 insured adults with proteinuric CKD. Using multivariable logistic regression, we estimated adjusted associations between current ACEI/ARB use and putative barriers including past acute kidney injury (AKI), hyperkalemia, advanced CKD, and lack of nephrology care.

Results

Only 49% (n=20,641) of patients had a

SUBMITTER: McCoy IE 

PROVIDER: S-EPMC8973200 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature